Wednesday, August 24, 2016 12:49:45 PM
Recent ALKS News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/24/2024 01:15:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 11:05:11 AM
- Alkermes plc Reports Third Quarter 2024 Financial Results • PR Newswire (US) • 10/24/2024 11:00:00 AM
- Alkermes plc Reports Third Quarter 2024 Financial Results • PR Newswire (US) • 10/24/2024 11:00:00 AM
- Alkermes to Report Third Quarter Financial Results on October 24, 2024 • PR Newswire (US) • 10/17/2024 08:00:00 PM
- Alkermes to Report Third Quarter Financial Results on October 24, 2024 • PR Newswire (US) • 10/17/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2024 08:07:13 PM
- Alkermes to Host Investor Event to Review Orexin Portfolio Strategy • PR Newswire (US) • 09/25/2024 12:00:00 PM
- Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 • PR Newswire (US) • 09/23/2024 11:00:00 AM
- Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference • PR Newswire (US) • 09/19/2024 08:00:00 PM
- Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program • PR Newswire (US) • 09/13/2024 11:00:00 AM
- Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program • PR Newswire (US) • 09/13/2024 11:00:00 AM
- Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:00:00 PM
- Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:00:00 PM
- Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 • PR Newswire (US) • 08/22/2024 11:00:00 AM
- Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 • PR Newswire (US) • 08/22/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 08:13:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/24/2024 08:59:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/24/2024 01:23:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:05:12 AM
- Alkermes plc Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 07/24/2024 11:00:00 AM
- Alkermes to Report Second Quarter Financial Results on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:00:00 PM
- Alkermes to Report Second Quarter Financial Results on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:56:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:55:11 AM
FEATURED Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • Oct 30, 2024 12:22 PM
FEATURED Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM